Repligen Corporation
RGEN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 32.75 | 0.73 | -2.62 | 0.21 |
| FCF Yield | 0.58% | 0.30% | 0.16% | 0.36% |
| EV / EBITDA | 173.31 | 158.06 | 195.91 | 237.23 |
| Quality | ||||
| ROIC | 0.52% | 0.41% | 0.18% | -1.18% |
| Gross Margin | 47.74% | 45.20% | 53.65% | 45.20% |
| Cash Conversion Ratio | 3.23 | 1.92 | 2.57 | -1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.75% | -1.82% | -5.08% | -7.50% |
| Free Cash Flow Growth | 109.01% | 83.57% | -60.79% | -30.82% |
| Safety | ||||
| Net Debt / EBITDA | -1.39 | -0.52 | -0.37 | -2.11 |
| Interest Coverage | 0.61 | 2.41 | 1.16 | -6.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.64 | 0.51 | 0.64 |
| Cash Conversion Cycle | 0.00 | 194.75 | 223.24 | 180.69 |